| Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment (NCT05435352) | Ourotech, Inc. | 2022-06-06 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study (NCT05067530) | Medical University of Gdansk | 2022-01-01 |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers (NCT04879849) | Takeda | 2021-09-09 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| Psychological Factors and Oncological Outcomes of Triple-negative Breast Cancer (NCT04669522) | Pius-Hospital Oldenburg | 2020-12-01 |
| Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer (NCT04489940) | EMD Serono Research & Development Institute, Inc. | 2020-10-12 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies (NCT04561362) | BicycleTx Limited | 2020-07-17 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (NCT04251533) | Novartis Pharmaceuticals | 2020-06-08 |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC (NCT04335669) | Lund University Hospital | 2019-12-20 |
| Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) (NCT04191135) | Merck Sharp & Dohme LLC | 2019-12-19 |
| Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy (NCT03199040) | Washington University School of Medicine | 2019-07-23 |
| Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (NCT03818685) | Centre Leon Berard | 2019-07-02 |
| Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (NCT03997123) | AstraZeneca | 2019-06-25 |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC (NCT03838367) | CytoDyn, Inc. | 2019-04-22 |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (NCT03742102) | AstraZeneca | 2018-12-21 |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer (NCT03692689) | Sinocelltech Ltd. | 2018-07-20 |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (NCT03310957) | Seagen Inc. | 2018-02-27 |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (NCT03396445) | Merck Sharp & Dohme LLC | 2018-02-18 |
| Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer (NCT03225547) | University of Chicago | 2018-02-12 |
| A Study of AK-01 (LY3295668) in Solid Tumors (NCT03092934) | Eli Lilly and Company | 2017-05-29 |
| Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR (NCT02720185) | University of Wisconsin, Madison | 2017-05-03 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (NCT03036488) | Merck Sharp & Dohme LLC | 2017-03-07 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) (NCT02978716) | G1 Therapeutics, Inc. | 2017-02-02 |
| Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (NCT02789332) | GBG Forschungs GmbH | 2016-09-01 |
| Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (NCT02926196) | Istituto Oncologico Veneto IRCCS | 2016-06-17 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer (NCT02685306) | Peregrine Pharmaceuticals | 2016-03-01 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) (NCT02622074) | Merck Sharp & Dohme LLC | 2016-01-27 |
| The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer (NCT02539017) | First Affiliated Hospital Xi'an Jiaotong University | 2015-11-01 |
| Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (NCT02427581) | Washington University School of Medicine | 2015-09-29 |
| Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy (NCT02348320) | Washington University School of Medicine | 2015-06-17 |
| A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations (NCT02299635) | Pfizer | 2015-02-03 |
| Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity (NCT02124902) | Washington University School of Medicine | 2014-07-07 |
| A Safety Study of SGN-LIV1A in Breast Cancer Patients (NCT01969643) | Seagen Inc. | 2013-10-22 |
| Triple-negative Breast Cancer: a New Perspective on Biomarkers (NCT03539965) | Instituto Nacional de Cancer, Brazil | 2010-01-01 |